Renalytix (RENX) has announced an “appointment of Oberon Capital (a trading name of Oberon Investments Limited) as joint corporate broker with immediate effect”. I suggest the question to ask on such announcements to be ‘how’s the company’s current financial position?’ – and even more so with there already two brokers, Stifel and Investec, here.
The idea of announcing a death spiral - while pretending it is not a death spiral - at the same time as a bailout placing, is odd. Who would want to buy into a placing, when you know that, at some point, a blizzard of confetti will be dumped?
Hello, Share Placers. This old punter is constantly searching out new medical pioneers to have a crack at. If things work out, you have the profits and the added bonus of helping to move medical technology further forward. But the risks are more than normal because new treatments and cures have to be carefully researched and then licensed. And quite a few horses never leave the stalls.









